AbbVie Faces Setbacks in Schizophrenia Drug Trials, Yet Maintains Hope
Exploring New Horizons Despite Challenges In recent developments, AbbVie has encountered difficulties with its leading schizophrenia medication, emraclidine, following disappointing results from two crucial Phase 2 trials. This treatment was a vital component of AbbVie’s significant $9 billion investment in Cerevel Therapeutics.